The Vector Group Ltd. (NYSE: VGR) announced
today that Dr. Anthony P. Albino, a renowned research director with over 30 years of
experience in cancer research and public health, has joined the Company as Vice
President for Public Health Affairs. Dr. Albino will be coordinating, implementing and
directing all public health initiatives for the Company.
Through its Vector Tobacco subsidiary, the Company is working to develop less
hazardous products, including a virtually nicotine-free cigarette and cigarettes with
significantly reduced levels of cancer-causing agents.
"Dr. Albino is an exceptionally talented individual with extensive experience in
both basic and clinical research and public health, and we are delighted to welcome him
to Vector," said Bennett S. LeBow, Chairman and Chief Executive Officer of the Vector
Group. "An expert in the field of Cancer Biology, Dr. Albino brings unparalleled
expertise to the area of tobacco-related research which will further strengthen Vector's capabilities."
"It is a tremendous honor to be named as the Vice President for Public Health Affairs,
and I look forward to working with the talented people at Vector at this extremely exciting
time," said Dr. Albino.
Most recently, Dr. Albino held the position of Deputy Director at the American
Health Foundation (AHF) Cancer Center in Valhalla, NY, an institution that has made
seminal contributions to our understanding of the impact of tobacco use. In addition, he
also served as AHF's Director of Research from 1997-2001, where he directed research
staff, developed a molecular biology program, and implemented productive scientific
associations with academic, industrial, and philanthropic organizations. Prior to joining
AHF, from 1995 –1997, Dr. Albino held the position of Director of Research at
Manhattan Eye, Ear, and Throat Hospital.
Previously, Dr. Albino served on the staff of the Memorial Sloan Kettering
Cancer Center from 1986-1995, where he led a research group, which made valuable
contributions to the understanding and treatment of skin, kidney, and gastric cancer.
In addition, Dr. Albino holds five patents for the identification and treatment of
melanoma, brain, and kidney cancer, and has published over 250 peer-reviewed research
articles, book chapters, and abstracts. He also served as both committee member and
chairperson on numerous national and international review committees for cancer
Dr. Albino graduated from Hunter College in 1970 with a Bachelor of Arts in
biology. He received his PhD from Cornell University in 1974 with a focus in Cancer
Vector Group is a holding company that indirectly owns Liggett Group Inc.,
Vector Tobacco and a controlling interest in New Valley Corporation. Effective May 24,
2000, Vector Group changed its name from Brooke Group Ltd.